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Abstract 
Introduction: Inherited macrothrombocytopenia represents a heterogeneous 
group of disorders which are characterised by the presence of a reduced 
number of abnormally large platelets in the circulation, which may or may 
not be associated with a bleeding tendency.  In spite of several causative 
genes having been identified, the underlying genetic defects remain to be 
identified in approximately half of the cases. 
Aims: To understand the molecular pathology of isolated giant platelet 
disorder from India. 
Materials and Methods: We studied 112 cases who were referred for 
investigation of macrothrombocytopenia. Agonist induced platelet 
aggregation and platelet GP1b/IX/V receptor expression were investigated 
to assess GP1b/IX/V receptor  expression and the GP1BA, GP1BB, GP9, 
ABCG5, ABCG8, TUBB1 and MYH9 genes were analysed to identify candidate 
gene defects.  
Results: Twenty three candidate gene defects were identified in 48 of 112 
cases, 20 of which were novel. Of the candidate defects identified, 91%  
were missense and 9% were nonsense variations. The missense variations were 
in GP9 (9), ABCG5 (4), GP1BB (3), GP1BA (3), and MYH9 (2), while the 
nonsense defects occurred in MYH9 (1) and GP1BA (1). 
Conclusions: This study increases the understanding of the molecular basis of 
an isolated giant platelet disorder, a common heterogeneous condition 
prevalent in North and Eastern India. 
 
Introduction 
Defined as a reduction in the number of platelets in the circulation, 
thrombocytopenia is usually an acquired disorder. However, defects in the 
genes regulating megakaryocyte differentiation and platelet production, 
which result in autosomal dominant or recessive, and X-linked forms of 
inherited thrombocytopenia, are increasingly being recognised [1-6]. Thus, 
while previously considered to be a rare disorder, it is now thought that the 
frequency of inherited thrombocytopenia may be underestimated. The 
variable clinical expression of inherited thrombocytopenia may contribute to 
its under diagnosis since some patients are asymptomatic and the relatively 
mild bleeding symptoms in others can frequently be overlooked until a low 
platelet count is detected often as part of a routine blood test [7]. In contrast, 
patients with more severe forms of inherited thrombocytopenia are usually 
identified early in the perinatal period, or at times of haemostatic challenge.  
Inherited macrothrombocytopenia, the most frequent form of inherited 
thrombocytopenia, represents a heterogeneous group of disorders 
characterised by a reduction in the number and an increase in the size of 
platelets. The molecular defects have been elucidated in a number of cases. 
A significant proportion of patients have autosomal dominantly inherited 
MYH9-related disorders which are due to defects in MYH9 that disrupt the 
assembly or stability of the myosin complex and cause profound 
abnormalities in the platelet cytoskeleton that can also be associated 
nephritis, deafness and cataracts [2].   
In 2002, Naina et al. described a form of inherited thrombocytopenia which 
appeared to be highly prevalent among healthy blood donors in the North-
Eastern states of the Indian subcontinent, affecting up to one third of healthy 
blood donors in West Bengal [5]. Termed Harris Platelet Syndrome (HPS), it was 
characterized by mild to severe macrothrombocytopenia, normal platelet 
function and an absence of inclusion bodies in the neutrophils. None of the 
donors had a history of excessive bleeding.  Preliminary family studies 
suggested an autosomal dominant mode of inheritance and also that 
defects in MYH9 were not involved. In contrast, none of the randomly 
selected donors from Tamil Nadu in Southern India were found to have 
macrothrombocytopenia. The apparent absence of MYH9-RD in HPS 
suggests that the spectrum of molecular defects underlying 
macrothrombocytopenia in the West Bengal population differs from that 
observed in other well characterised cohorts of patients with inherited 
thrombocytopenia which, to date, have mainly been of European and 
Eastern origins. These findings also suggest that founder effects may 
contribute to the high prevalence of macrothrombocytopenia in the North 
East, compared to the South of India.     
In this study we have investigated the clinical expression and molecular basis 
of inherited macrothrombocytopenia in 112 index cases, the majority of 
whom originated from West Bengal and the North-Eastern states of India and 
Nepal. Analysis of genes that have previously been associated with inherited 
macrothrombocytopenia identified candidate defects in 48 index cases 
leading us to conclude that inherited macrothrombocytopenia is a 
heterogeneous disorder in this population.  
Materials and Methods 
Study subjects and Methods 
One hundred and twelve unrelated cases, who were referred to the 
Department of Haemostasis, National Institute of Immunohaematology, 
Mumbai or the Department of Haematology, NRS Medical College, Kolkata 
for investigation of macrothrombocytopenia, were studied. Cases were 
enrolled in the study if they had a reduced platelet count (<150 X 109/L) and 
a mean platelet volume (MPV) greater than 10fl which was associated with 
the presence of giant platelets as revealed by light microscopic examination 
of a peripheral blood smear. In some cases, the MPV was greater than 18.5fl 
and could not be determined by the cell counter, but the presence of giant 
platelets was confirmed by examination of the peripheral blood smear. 
 All cases had normal anti-platelet antibody [8], and ferritin levels, and were 
grouped according to whether they had mild (100-150 X 109/L), moderate 
(50-100 X 109/L) or severe (<50 X 109/L) thrombocytopenia. A detailed clinical 
history, including age of onset and type of any bleeding symptoms was 
recorded for each case, using the World Health Organisation (WHO) 
bleeding scale (grade 0, no bleeding; grade 1, petechiae; grade 2, mild 
blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss) to score 
the severity of bleeding symptoms. A family history of bleeding symptoms and 
information on consanguinity, were also obtained. 
Candidate gene defects identified in the index cases were sought in 
genomic DNA from 100 healthy control subjects (Age Range: 10-65 years; 
Male/Female: 52/48) all of whom had normal platelet counts (>200 X 109/L), 
and MPV less than 10 fl and were also enrolled in the study.    
The study was approved by the ethics committee and undertaken in 
accordance with the ethical guidance of the institution involved (No. 
IIH/IEC/11-2007). Written, informed consent was obtained from all study 
subjects (cases and controls) prior to the collection of citrated and EDTA 
blood samples for phenotypic and genotypic analyses.  
Laboratory Investigations 
Coagulation tests to exclude a plasma factor deficiency included a 
prothrombin time (PT) with neoplastin CI plus (Diagnostica Stago, Paris, 
France), activated partial thromboplastin time (APTT) with actin activated 
cephaloplastin reagent (Dade Behring FSL, Marburg, Germany), and 
thrombin time (TT) with commercial bovine thrombin (Baxter Diagnostic Inc. 
Dade Dives-USA). All assays were carried out in a semi-automated 
coagulometer (Start 4, Diagnostica Stago, France) as described previously 
[9]. Full blood counts were determined on samples taken into EDTA using the 
XT-2000i cell counter (Transasia Bio-Medical Ltd, Mumbai, India) within 2 hours 
of collection. Peripheral blood smears were stained using modified 
/HLVKPDQ·VVWDLQDQGHYDOXDWHGE\OLJKWPLFURVFRS\ 
Platelet rich plasma (PRP) was prepared by centrifugation at 100g for 10 mins 
and in vitro platelet aggregation in response to ristocetin (0.5 and 1.25 
mg/ml), adenosine diphosphate (ADP) (5µM), arachidonic acid (AA) 
(0.75mM) and collagen (2 µg/ml) was assessed using a lumi-aggregometer 
(Chronolog, Haverton, PA, USA). Expression of platelet membrane 
glycoproteins was assessed by flow cytometry in samples of PRP which were 
diluted with phosphate buffered saline, before being incubated with 
fluorescein isothiocyanate (FITC) conjugated monoclonal anti-human GPIb 
(CD42b), GPIX (CD42a) or phycoerythrin (PE) conjugated anti-GPIIb/IIIa 
(CD41a) antibodies, or the appropriate IgG1 and IgG2a isotype control 
antibodies (BD Biosciences, Pharmingen, San Jose, CA, USA). Following 
incubation, platelets were analysed for cell bound fluorescence in a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). 
Genotyping Studies 
Genomic DNA was extracted from peripheral blood samples using a 
standard phenol-chloroform method and quantified using a 
NanodropTM1000 spectrophotometer (Thermo Scientific). Sequencing of 
coding and non-coding regions of GP1BA, GP1BB, GP9, TUBB1, MYH9, ABCG5 
and ABCG8 was then undertaken to identify candidate gene defects. 
PCRs contained DFS10X complete reaction buffer and DFS-Taq polymerase 
(5U/Pl) (BIORON GmbH, Germany), 10pmoles of each primer, 25mM dNTPs, 
25mM MgCl2 and 100ng of genomic DNA in a final volume of 25Pl. PCRs were 
subjected to an initial denaturation step at 95°C for 5 minutes followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing of the primers at 
different temperatures for 45 seconds and elongation at 72°C for 1 minute. 
The final elongation step was carried out at 72°C for 10 minutes before 
incubating the PCR products at 4°C. The sequences of all primers and 
annealing temperatures of PCRs are shown in supplementary Table 1. PCR 
products were purified either by electrophoresis followed by gel extraction 
(QIAGEN Ltd, Manchester, UK) or by treatment with ExoSAP-IT (GE Healthcare, 
Little Chalfont, UK), before being sequenced in both directions using BigDye® 
Terminator v3.1 Cycle Sequencing (Applied Biosystems, Paisley, UK) and 
sequence analysis was performed on an ABI PRISM 3130xl Genetic Analyzer 
(Applied Biosystems).  
In Silico Analysis 
Sequencher v4.9 (http://www.genecodes.com) was used for DNA sequence 
assembly. The functional importance of candidate missense variations was 
investigated using Align GVGD (http://agvgd.iarc.fr), Sorting Intolerant from 
Tolerant (SIFT; http://sift.bii.a-star.edu.sg/) and Polymorphism Phenotyping v2 
(PolyPhen-2; http://genetics.bwh.harvard.edu/pph/) [10]. The positions of 
amino acids and nucleotides were denoted using Human Genome Variation 
Society (HGVS) nomenclature (www.hgvs.org) and checked using Mutalyzer 
(https://mutalyzer.nl/check?name). The effects of amino acid substitutions 
caused by candidate single nucleotide variations on protein stability were 
predicted using I-Mutant2.0 (http://folding.biofold.org/i-mutant/i-
mutant2.0.html) [11] and MUpro (http://mupro.proteomics.ics.uci.edu/) [12]. 
All the above online tools were accessed in December 2014. 
Statistical Analysis 
Data were analysed using INSTAT Graphpad analyser 
(graphpad.com/scientific-software/instat/) using Spearman·V rank correlation 
method. P values <0.05 were considered significant [13]. 
Results  
Clinical and Phenotypic Features of the Index cases 
The clinical features of the index cases are summarised in Table 2. The cases 
comprised 55 females (median age 25 years; range 8-70 years) and 57 males 
(median age 30 years; range 8- 70 years) (Table 3). The geographic 
distribution of cases across India is shown in (Fig. 1). Of the cases, 68 (61%) 
reported no history of bleeding symptoms (grade O), and 44 (39%) of the 
patients had bleeding manifestations; 6(5%) had grade 1 bleeding 
(petechiae), 18 (16%) had grade 2 bleeding (mild blood loss), 16 (14%) had 
grade 3 bleeding (gross blood loss) and only 4 (4%) patients reported  grade 
4 bleeding symptoms (debilitating blood loss). Predominant clinical 
manifestations were easy bruising 4 (4%), ecchymosis 8 (7%), epistaxis 18 
(16%), frequent gum bleeding 6 (5%), menorrhagia 11 (10%) and a prolonged 
history of bleeding after trauma 7 (6%). One male, BM35.01, who had a 
history of frequent gum bleeds and two females who reported menorrhagia, 
BM78.01 & BM105.01, had previously required transfusions for excessive 
bleeding. Of the 68 asymptomatic cases, the majority of whom were 
identified incidentally during routine analysis of blood samples, 12 had a 
family history of bleeding and 3 had a personal history of transfusion in the 
past. There was no known consanguinity amongst the cases studied. The 
study of inheritance pattern in two index cases (BM15.01 & BM27.01) and their 
family members showed dominant mode of inheritance (Fig. 2). 
Examination of peripheral blood smears, which were available for all but one 
index case, BM46.01, confirmed the diagnosis of macrothrombocytopenia, 
and revealed the presence of stomatocytes in the red blood cells from 10 
cases (Fig. 3), and the absence of leukocyte inclusion bodies, in all cases.  
There was a wide variation in platelet count among the cases; 45(40%) had 
mild thrombocytopenia, 54 (48%) had moderate thrombocytopenia, and 12 
(11%) had severe thrombocytopenia which has resulted in their referral for 
investigation of bleeding problems. One patient had a normal platelet count 
but the peripheral blood smear revealed the presence of abnormally large 
platelets. The median MPV among the cases was 13.25 fl (range 12 - 16.5fl). 
The WHO bleeding score showed a significant inverse correlation with 
platelet count (P=0.016) and direct significant correlation with MPV (P=0.010) 
among the cases (Fig 3).  
The results of screening coagulation tests were within the normal ranges in all 
the cases. Platelet aggregation and receptor study showed reduced 
expression for cases with low platelet count to normal expression for cases 
with mild to moderate platelet count. 
Circulating platelet counts were within the normal range (mean platelet 
count 197.3, SEM 3.275), and peripheral blood smears confirmed the 
presence of normal sized platelets (mean MPV 11.09, SEM 0.074) in samples 
from all control subjects.  
Genetic Investigations 
A total of 23 heterozygous candidate single nucleotide variations (SNVs) 
affecting GP9 (18 cases), ABCG5 (12 cases), MYH9 (11cases), GP1BA (4 
cases) and GP1BB (3 cases) were identified in 48 of the 112 index cases 
(Table 2). Of these, 21 were non-synonymous variations that predicted amino 
acid substitutions in the encoded protein. The remaining two were nonsense 
variations, one in GP1BA and another in MYH9. The majority of the SNVs 
identified (20/23) were novel. Three SNVs had been previously reported; 
c.5797C>T (p.Arg1933*) in MYH9, and c.148C>T (p.Arg50Cys) and c.293C>G 
(p.Ala98Gly) in ABCG5 (Table 2). Ten recurrent SNVs were identified, three in 
MYH9 (p.Asp1948Asn, n=7; p.Glu1946Lys, n=2; p.Arg1933*, n=2), four in ABCG5 
(p.Arg50Cys, n=6; p.Asn551Lys, n=2; p.Ala98Gly, n=2; p.Asp71Asn, n=2) and 
three in GP9 (p.Ser62Thr, n=4; p.Arg97Pro, n=4; p.Arg39Gly, n=4). No 
sequence alterations were detected in either TUBB1 or ABCG8 in DNA from 
the first 50 index cases investigated. These genes were therefore not analysed 
in the remainder of the cases. None of the alterations identified among the 
cases, were detected among the control subjects.   
Comparison of the allelic distributions of several common polymorphisms of 
GP9, GPIBA, ABCG5 and TUBB1 revealed a significant association between 
two GP9 polymorphisms and macrothrombocytopenia. SNP rs6069 [c.132 
G>A (p.Thr44=), a silent change (OR= 0.16 95% CI=0.07-0.37, P< 0.0001)] and 
rs3796130 [c.466G>A (p.Ala156Thr) (OR= 0.13 95% CI=0.03 to 0.51], P=0.0034)], 
the risk/rare allele A for both SNP was found to be significantly associated 
with macrothrombocytopenia (Table 4). 
In silico predictions of effects of candidate SNVs  
Seventeen of the 20 novel missense changes identified in the study were 
predicted to be deleterious to protein function and stability (Table 5). Three 
SNVs, two predicting p.Leu176Arg and p.Gln76His substitutions in GPIX, and a 
third predicting a p.Glu1946Lys substitution in non-muscle myosin heavy chain 
9 were predicted to have benign or borderline effects on protein function 
using two bioinformatic tools (PolyPhen and SIFT). However, all three of these 
alterations were also predicted to decrease the stability of the corresponding 
proteins using the MUPRO/I-Mutant 2.0 predictive tool (Table 5).  
Genotype-Phenotype Correlation  
We examined the association between candidate gene defects and 
bleeding severity (as indicated by the WHO bleeding score) among those 
index cases who were heterozygous for recurrent candidate gene defects. 
The c.115 A>G (p.Arg39Gly) SNV in GP9 was detected in 4 cases; 1 with 
severe thrombocytopenia, menorrhagia and with a bleeding score of 3, and 
three with moderate thrombocytopenia, two of whom had no bleeding 
diathesis (bleeding score 0) and a third who had frequent gum bleeds 
(bleeding score 3). The c.293 C>G (p.Ala98Gly) SNV in ABCG5 was identified 
in 2 index cases with moderate thrombocytopenia, one having a bleeding of 
score of 0 and the other having a score of 4. A The c.148C>T (p.Arg50Cys) 
SNV in ABCG5 was associated with mild to moderate thrombocytopenia 
among 6 index cases, four of whom were asymptomatic, while the other two 
index cases reported histories of either ecchymosis and epistaxis (bleeding 
score 2), or of ecchymosis alone (bleeding score 1).  Similarly, the c.211G>A 
(p.Asp71Asn) ABCG5 SNV was present in one asymptomatic index case and 
another with a history of epistaxis. The c.5797C>T (p.Arg1933*) nonsense 
alteration in MYH9 was detected in two cases, one of whom was 
asymptomatic, while the second had a bleeding score of 2. Similarly, the 
c.5842 G>A (p.Asp1948Asn) SNV in MYH9 was associated with variable 
symptoms among the 7 index cases who inherited this alteration (Table 2).  
No correlation could be established between mutations and phenotype in 
Bengal Macrothrombocytopenia cases (BM) (Table 2). 
Discussion  
Previous studies which have observed a high prevalence of a mild to severe 
form of non-MYH9 related macrothrombocytopenia among healthy blood 
donors in the north Eastern states of India, suggest that founder effects may 
contribute to the prevalence of macrothrombocytopenia in this geographic 
region. In this study, we have described the clinical expression of inherited 
macrothrombocytopenia in 112 index cases originating primarily from West 
Bengal and the North-Eastern states of India and Nepal. The majority (61%) of 
the index cases were asymptomatic and were identified incidentally as a 
result of routine blood tests, while the remainder of the index cases reported 
symptoms consistent with the presence of a platelet bleeding disorder.  
Analysis of a panel of genes which have been associated with inherited 
macrothrombocytopenia in other populations revealed candidate gene 
defects in 48 of the 112 (43%) index cases confirming the underlying 
heterogeneity of the macrothrombocytopenia in this population, with 
candidate gene defects being identified in GP1BA (n=4), GP1BB (n=3), GP9 
(n=18), ABCG5 (n=12) and MYH9 (n=11).  
Examination of peripheral blood smears was possible for all but one index 
case. Interestingly, none of the MYH9 gene defects identified in this study was 
associated with the presence of neutrophil inclusion bodies, and further work 
using immunofluorescent staining of non-muscle myosin would be required to 
determine whether the novel MYH9 defects identified in these patients are 
associated with abnormal distribution of myosin in peripheral blood 
neutrophils. Unfortunately, it was not possible to examine a peripheral blood 
smear from the index case who was heterozygous for the MYH9 nonsense 
variation, p.Arg1933* which we would expect to be associated with the 
presence of neutrophil inclusion bodies [14]. Of note, the MYH9 defects 
predicting the p.Asp1948Asn, p.Glu1946Lys alterations affected residues in the 
non-helical tail region of the myosin heavy chain defects in which have 
previously been reported to be associated with a milder bleeding diathesis 
[15-16].  
Examination of peripheral blood smears revealed the presence of 
stomatocytes in the red blood cells from 10 index cases, which, in addition to 
the presence of giant platelets, is a recognised haematological feature of 
sitosterolaemia [3, 17]. Subsequent analysis of ABCG5 and ABCG8, the genes 
which have previously been shown to harbour defects in patients with 
sitosterolaemia and macrothrombocytopenia [18],  revealed candidate 
defects in ABCG5 in all ten cases; p.Asn551Lys (BM7.01); p.Ala98Gly 
(BM38.01); p.Asp71Asn (BM109.01 and BM110.01) and p.Arg50Cys (BM14.01, 
BM68.01, BM83.01, BM89.01, BM90.01 & BM96.01).Interestingly, the ABCG5 
defect predicting the p.Arg50Cys substitution was present in 6 index cases 
suggestive of a possible founder effect for this alteration in the population 
studied.   
Several SNVs were identified in the genes encoding the platelet GPIb-IX-V 
receptor complex. Thus, heterozygous SNVs affecting GP1BA were identified 
in four cases, three non-synonymous SNVs predicting a p.Leu10Val 
substitution in the signal peptide of GPIBA, a p.Pro454Ser substitution in the 
Proline/Threonine rich region, and a p.Leu213Arg substitution in the Leucine 
rich repeat region, and a nonsense variant, introducing a premature stop 
codon (p.Leu488*). Three non-synonymous SNVs were identified in GP1BB, all 
predicting substitutions of amino acids in the conserved leucine rich repeats 
of the cytoplasmic tail of GPIB%c.285C>G, p.Cys95Trp; c.338A>T, 
p.Tyr113Phe; c.320G>C, p.Arg107Pro). 
Bernard Soulier Syndrome (BSS) and Sitosterolaemia (Mediterranean 
stomatocytosis/macrothrombocytopenia) are classically described as 
recessive disorders and heterozygous carriers of these disorders are usually 
asymptomatic or have mild bleeding symptoms [19-22].  Supporting this, the 
cases studied here who were heterozygous for candidate defects in GPIBA, 
GPIBB and ABCG5 were either asymptomatic or had mild to moderate 
bleeding symptoms.  Three GP1BA defects which predict p.Ala172Val, 
p.Tyr70Asp, and p.Leu73Phe substitutions in GPIBA, have been reported to 
give rise to BSS with a dominant mode of inheritance along with the classical 
form of BSS when the defects are homozygously inherited [23-26]. One of 
these, p.Ala172Val, which is also known as the Bolzano mutation is frequently 
found in the Italian population [19].  In GP1BB, heterozygous defects 
predicting the amino acid substitutions, p.Arg42Cys and p.Ala133Pro give rise 
to isolated giant platelet disorder [27-28] while the p.Tyr113Cys substitution 
reported in several Japanese families suppresses expression of the GP1b/IX/V 
complex, giving rise to a BSS-like bleeding disorder when homozygously 
inherited and to isolated giant platelet disorder when heterozygously 
inherited [29]. 
The frequency of 2 SNVs in GP9; rs6069 (p.Thr44=), a synonymous change with 
minor allele frequency of 0.0583 and rs3796130 (p.Ala156Thr) with a minor 
allele frequency of 0.0675, were observed to be more prevalent in cases than 
in control subjects and were significantly associated with the disorder (Table 
4). p.Ala156Thr was reported to be associated with low platelet count and 
also alters the protein function [30] and has a damaging effect on the 
protein stability as predicated by different tools (Table 5). 
The identification of candidate defects in genes which have previously been 
associated with macrothrombocytopenia in 48 of the 112 cases studied here, 
lead us to conclude that inherited macrothrombocytopenia is a 
heterogeneous disorder in India. Further study will be required to identify the 
gene defects underlying macrothrombocytopenia in the remaining 64 (57%) 
cases without mutations in the genes investigated here.  
Greater awareness of  this condition will reduce the risk of misdiagnosis and 
the potential for inappropriate treatment of affected individuals which is 
important given that congenital macrothrombocytopenia is a common and 
under diagnosed condition in India [5, 31]. 
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Table 1: Oligonucleotide Primer Sequences 
Gene Name Location Primer Name Orientation 6HTXHQFH·-·   Annealing 
Temperature 
Product 
Size (bp) 
GP1BA Exon2 1b1_F Forward AGGTCTTTCTGCCTGCCTGT 600C 774 
  1b1_R Reverse TAGCCAGACTGAGCTTCTCC 600C  
 Exon2 1b2_F Forward AAGGCAATGAGCTGAAGACC 590C 597 
  1b2_R Reverse CTTGTGTTGGATGCAAGGAG 590C  
 Exon2 1b3_F Forward TCCACTGCTTCTCTAGACAG 650C 515 
  1b3_R Reverse GGCTGATCAAGTTCAGGGAT 650C  
 Exon2 1b4_F Forward CACAAGCCTGATCACTCCAA 590C 585 
  1b4_R Reverse TTCTCTCAAGGTCCCCAAAC 590C  
GP1BB ·875 GP1bb1_F Forward AGGATCCTGGGTCTGTTCCC 710C 775 
  GP1bb1_R Reverse CGACCGGACTCCAGACTCAC 710C  
 Exon 2 GP1bb2_F Forward TTACTGCGGCGCTTCCCTTG 650C 492 
  GP1bb2_R Reverse AAGGCCAGCAGCGCAAGCT 650C  
 ·875 GP1bb3_F Forward AGCTTGCGCTGCTGGGCCTT 650C 545 
  GP1bb3_R Reverse TGTCCCCTTGAACCGCCTCC 650C  
GP9 981-1560 GPIX_F Forward TGTTCCTGCTCTGGGCCACA 600C 586 
  GPIX_R Reverse TTGGTGGAGTCTGGGGACCT 600C  
MYH9 Exon 2 MYH9_2F Forward GAGGTGTGAGCATGAGTGATCTTG 680C  512 
  MYH9_2R Reverse CGTGAGGGTGATGGGAAGACC 680C  
 Exon 3 MYH9_3F Forward CTCACGATGACAAAGACATCTCTC 680C 598 
  MYH9_3R Reverse CTTAGCACCTGCAAAGGTGTCAAT 680C  
 Exon 4 MYH9_4F Forward GGGCAGCTCTTTGGGAGCAAGGTGGG 680C 205 
  MYH9_4R Reverse TGGGGGACTCTGCAAGCCCCAGTTGTG 680C  
 Exon 5 MYH9_5F Forward GTTGGGTCCTTCACGGGCACC 680C 319 
  MYH9_5R Reverse CAAAGCATCCTCTTGTAAAGCTGAAGCC 680C  
 Exon 6 MYH9_6F Forward CGGCTCTGCCATCGTCCCCCTT 680C 255 
  MYH9_6R Reverse AAAGGCAGCATGAGCCAAAGCTCCG 680C  
 Exon 7 MYH9_7F Forward CCGTCTCTGGGTTTTCTCCCTCCAA 680C 324 
  MYH9_7R Reverse CTCCACAGAGAAGGTGTCAGGATGG 680C  
 Exon 8 MYH9_8F Forward AGAATCGCTTGAATCCAGGAGGTG 680C 354 
  MYH9_8R Reverse TTCATTTCCCAAATGATGTCTACGG 680C  
 Exon 9 MYH9_9F Forward TCTGTCCCAGTCTCTCCAACCTTT 680C 389 
  MYH9_9R Reverse AGGAATCATTTTCCCATACACTGAAGG 680C  
 Exon 10 MYH9_10F Forward CTTGTCTGGCTTGAGGATCCCTAGAT 680C 277 
  MYH9_10R Reverse AATTTCCGCAAGACCTTCCCTCCTGA 680C  
 Exon 11 MYH9_11F Forward GGGTCTAATTAGAACTTTCTCTCTTGGG 680C 314 
  MYH9_11R Reverse GGAATCATGTGAAAGTGCCTGACAC 680C  
 Exon 12 MYH9_12F Forward AAAGTGAAATTACTGGGGCATAGGG 680C 316 
  MYH9_12R Reverse GAAGCAGGGTTCTTAACCAAGGATAA 680C  
 Exon 13 MYH9_13F Forward TTCCTGTATCCCTGCCCCACCCTCCTT 680C 359 
  MYH9_13R Reverse CAACCAACACAGAGCTGAGGTGAGGAG 680C  
 Exon 14 MYH9_14F Forward GATTCAGGGGATTCTGATGTCCGGG 680C 346 
  MYH9_14R Reverse TCCTGGTCCTAGAGAGCCTCGAC 680C  
 Exon 15 MYH9_15F Forward TCGCTCCCCTTATCCTCACCACTTCCT 680C 393 
  MYH9_15R Reverse TCAGGGGGCACATGTGTACCCCTTGT 680C  
 Exon16 MYH9_16F Forward TCCGACGTGTGCCTGTCTCTCTCT 680C 364 
  MYH9_16R Reverse TTTGCTGGGGAGACAGACAAGGGC 680C  
 Exon 17 MYH9_17F Forward CCCTGTCAGGTTCATAGGGGTTC 680C 347 
  MYH9_17R Reverse GGCCAGACTCAGTTCTACATGGATG 680C  
 Exon 18 MYH9_18F Forward GGTGGGATTTGCCTGTGTCTTCTTTCC 680C 332 
  MYH9_18R Reverse GGCATCCACCGACCACTGATATAGCAA 680C  
 Exon 19 MYH9_19F Forward TCAGCCAGTGAGAAGAAGGGTGAA 680C 435 
  MYH9_19R Reverse CCTCAAAGGTAGAAATCCAGGAACAG 680C  
 Exon 20 MYH9_20F Forward TTGAGGACAAGACCAGGACTGTTA 680C 261 
  MYH9_20R Reverse ACAAACAATTAGCCAGGTATGTATGG 680C  
 Exon 21 MYH9_21F Forward CCACCACAGCGTGTCTTCTTGCC 680C 349 
  MYH9_21R Reverse AAACTTCCAGCATGCCGTGCCTAC 680C  
 Exon 22 MYH9_22F Forward TGGAAGGTACCTGGAAGCTTCAGAGC 680C 479 
  MYH9_22R Reverse GAGGAGCAGCCTCCTTGGACCCTAA 680C  
 Exon 23 MYH9_23F Forward CCTTCGGACCTTGCTGCCTTCAC 680C 288 
  MYH9_23R Reverse CCCTGCAAGGGTGACCACACTC 680C  
 Exon 24 MYH9_24F Forward CCGGGCGAGTCATGCTTTGA 680C 294 
  MYH9_24R Reverse CTCGGTGTTCCGGTCAGACA 680C  
 Exon 25 MYH9_25F Forward TGCGAGTGTCTGTGTGTTTGTGATG 680C 416 
  MYH9_25R Reverse GTGGAAAGAATGCTCACAGCTCACTA 680C  
 Exon 26 MYH9_26F Forward TCAGGCCTGTCCTGCAAACTCTGCT 680C 423 
  MYH9_26R Reverse TTCCATGCCTGCTGGTGCCTAAGAG 680C  
 Exon 27 MYH9_27F Forward AGAAAAGCTGCCTGGAGTGCCTGTG 680C 347 
  MYH9_27R Reverse GCTCTGCAGGACTGGTTTGGATTCTG 680C  
 Exon 28 MYH9_28F Forward GGTCCAGTGATGATAGACCAGCCA 680C 390 
  MYH9_28R Reverse GCCAGTTTGAGAAGAGAGAGAGACAG 680C  
 Exon 29 MYH9_29F Forward CTGTCTCTCTCTCTTCTCAAACTGGC 680C 329 
  MYH9_29R Reverse GGCTCTGAAGCTAATGTTGCGTGG 680C  
 Exon 30 MYH9_30F Forward TCCCTCTCCTCAAGGGTGTGGGGTT 680C 394 
  MYH9_30R Reverse CCTTGAGAGCACTGATGTGGGAGAGCA 680C  
 Exon 31 MYH9_31F Forward GGTTTCATAACTGGGCAGATCCCT 680C 530 
  MYH9_31R Reverse AGCCTGAGGGTCCTCTAAGCACTG 680C  
 Exon 32 MYH9_32F Forward ACTGTGTGTATTGTCCTGGGC 680C 504 
  MYH9_32R Reverse AAGTCAGGAGCAAAGGGACT 680C  
 Exon 33 MYH9_33F Forward GGAGGACCTTATGAGCTCCAAG 680C 479 
  MYH9_33R Reverse CAGGTGGAAGGAGAGAACAGAA 680C  
 Exon 34 MYH9_34F Forward CCATGGATCCTGCAGAACT 680C 385 
  MYH9_34R Reverse GGACCTTCCCAGGAGGTG 680C  
 Exon 35 MYH9_35F Forward ATACAGCATTGAGTGGAGCACCAGC 680C 324 
  MYH9_35R Reverse CCTGTCCTCAGCTGAAAGCCCCA 680C  
 Exon 36&37 MYH9_36 &37F Forward GTGAGCTAGAGGGTTTCTGGAGGAA 680C 575 
  MYH9_36 &37R Reverse GGTGCCTGGACATTTTCCCCTAAG 680C  
 Exon 38 MYH9_38F Forward TTCTGGGAGACCCAAGACTCTGGAC 680C 442 
  MYH9_38R Reverse TCAGGAGACAGAGAGCTGGTTGTGG 680C  
 Exon 39 MYH9_39F Forward TGGGTGGTCCTGGTTAGGGCTTGTT 680C 362 
  MYH9_39R Reverse CTTGAGCTGCTTCAGGCGGGTAGAT 680C  
 Exon 40 MYH9_40F Forward GAGCGGAGGAACGCCGAGCAGTACA 680C 432 
  MYH9_40R Reverse CGTGCCTTGCTTGTGGGCTCTGGTTGA 680C  
 Exon 41 MYH9_41F Forward TTGAGATGTGTGGGCTGTGCTG 680C       301 
  MYH9_41R Reverse TCACAGCAGTCCCAAGAAGGTG 680C  
ABCG5 Exon 1 ABCG5_1F Forward CCAACTGAAGCCACTCTGG 580C 293 
  ABCG5_1R Reverse AAGAGTGAAGAAAGGCAGCA 580C  
 Exon 2 ABCG5_2F Forward CACAGGTAGGATCAATGCTG 580C 305 
  ABCG5_2R Reverse CAAACCTGTGGCTTTCTTGT 580C  
 Exon 3 & 4 ABCG5_3&4F Forward CACAGAGGGTCTCGGGAAG 600C 499 
  ABCG5_3&4R Reverse GAGTGACGAGCAAAGGGAAG 600C  
 Exon 5 ABCG5_5F Forward GTGTGCTGCCTCTTTCATGT 600C 283 
  ABCG5_5R Reverse TGCACACACACAGAAGATGC 600C  
 Exon 6 ABCG5_6F Forward GTTTACTTCCCACCGCACACT 600C 322 
  ABCG5_6R Reverse GATTCCCAGCTCAACACACCA 600C  
 Exon 7 ABCG5_7F Forward CCAGAGACATTCAAAGTGCA 580C 267 
  ABCG5_7R Reverse TCCAGGCAGAAGTCTGAGAT 580C  
 Exon 8 ABCG5_8F Forward GGCCAGTACTCCTGTACCAA 580C 361 
  ABCG5_8R Reverse GTTATTGGGGGATGGCTAAA 580C  
 Exon 9 ABCG5_9F Forward TAGCCATCCCCCAATAACAAT 600C 300 
  ABCG5_9R Reverse GAGAAAGAGGTGCACCTCCAG 600C  
 Exon 10 ABCG5_10F Forward AGACCTCACATTCAGCTTGG 600C 283 
  ABCG5_10R Reverse TCCCACTAGCTCCATGACTC 600C  
 Exon 11 ABCG5_11F Forward TCACAGAGGCAAGTGCAGTA 600C 348 
  ABCG5_11R Reverse TCTGGTATTCCTTTACTTCAGTCAT 600C  
 Exon 12 ABCG5_12F Forward TTGCCTTTCTTTTCATTTGG 580C 246 
  ABCG5_12R Reverse CCAAGAAATTGCTTCCTCAG 580C  
 Exon 13 ABCG5_13F Forward ACCTGAGATAAACCACACCTG 600C 298 
  ABCG5_13R Reverse TCAGAGCAGTCATGCACAGT 600C  
ABCG8 Exon 1 ABCG8_1F Forward GCAAGGAATGCTGGGAGAG 600C 286 
  ABCG8_1R Reverse AGGCTCCTGAGGGAAGAGAG 600C  
 Exon 2 ABCG8_2F Forward GCCCACCCTTTTATTTCCAC 600C 270 
  ABCG8_2R Reverse GCCCACCCTTTTATTTCCAC 600C  
 Exon 3 ABCG8_3F Forward TGAAGCCCTCTGAACCATTC 600C 256 
  ABCG8_3R Reverse TCCCAGGAGAGAAACCATTG 600C  
 Exon 4 ABCG8_4F Forward GGAGAGTGTATGGGGAGCAG 600C 449 
  ABCG8_4R Reverse GGAAGGCAAGCTGAGTTGTT 600C  
 Exon 5 & 6 ABCG8_5&6F Forward CCTTTATCCTTGGGGTCACA 600C 667 
  ABCG8_5&6R Reverse AAGCTTGGGCAGGGTTTAAG 600C  
 Exon 7 & 8 ABCG8_7&8F Forward GGTGATCAGCATTGTGAGCTG 620C 596 
  ABCG8_7&8R Reverse CTGGGATTACAGGCATAAGCC 620C  
 Exon 9 ABCG8_9F Forward CCCCATTTTGCATAGGAGAA 620C 369 
  ABCG8_9R Reverse AGGAACACAGCTTGGAGGTG 620C  
 Exon 10 ABCG8_10F Forward AGTCTCCAAAACAGAAGCACTG 640C 223 
  ABCG8_10R Reverse TGTAGCAACGTTTTCTCCACA 640C  
 Exon 11 ABCG8_11F Forward AGTGAAGGTGCTGGCTTCAT 600C 379 
  ABCG8_11R Reverse AGCAGGCTTCATCCAGTCAC 600C  
 Exon 12 & 13 ABCG8_12&13F Forward CGAATATGGGGAAACCATGA 600C 467 
  ABCG8_12&13F Reverse TTGAAGGGTCTGCTCAGGTC 600C  
TUBB1 Exon 1 TUBB1_EX1F Forward AACCGAAGCTCTGGATTCTG 600C 269 
  TUBB1_EX1R Reverse AAGCCCAAAGGCATTGTCTG 600C  
 Exon 2 TUBB1_EX2F Forward TTTCTCTGTGGTTAACACAGC 550C 283 
  TUBB1_EX1R Reverse CTGAGCATAGACATCACTGC 550C  
 Exon 3 TUBB1_EX3F Forward TGGACCAGTATCACAAAGTTC 550C 726 
  TUBB1_EX3R Reverse CTCATGGTCAAGGACACTAG 550C  
 
 
 
 
 
 
Table 2: Phenotypic and genotypic features of Congenital Macrothrombocytopenia cases from India 
Patient ID Sex AOD
(Yrs) 
Clinical 
Manifestations/
WHO Bleeding 
Score 
Family 
History  
of 
Bleeding 
Platelet 
Count 
(X10
9
/L) 
NR:150-450 
MPV 
(fl) 
NR: 7.8-10.2 
           
Mutation 
Gene cDNA
a
 Protein 
          
BM1.01 M 19 0/0 No 91 12 GP9 c.185 G>C p.Ser62Thr 
BM2.01 M 25 0/0 No 66 12.5 GP9 c.146 T>G p. Leu49Arg 
BM3.01 M 30 0/0 No 145 13 NMD   
BM4.01 M 20 0/0 No 81 13 NMD   
BM5.01 F 28 4/2 Yes 107 12 NMD   
BM6.01 M 30 1/1 No 51 13.9 GP9 c.290 G>C p. Arg97Pro 
BM7.01 F 32 3/3 No 54 13 ABCG5 c.1653 C>G p. Asn551Lys 
BM8.01 F 67 0/0 No 65 12.9 GP9 c.115 A>G p. Arg39Gly 
BM9.01 M 70 0/0 No 73 12 NMD   
BM10.01 F 37 1,4/2 yes 77 12.5 GP1BB c.285 C>G p.Cys95Trp 
BM11.01 F 60 0/0 No 90 12 NMD   
BM12.01 M 42 0/0 No 74 >18.5* NMD   
BM13.01 M 40 0/0 No 109 13.1 NMD   
BM14.01 F 17 2, 4/2 No 140 13.3 ABCG5 c.148 C>T p.Arg50Cys
k
 
BM15.01 M 30 5/4 Yes 27 14.1 NMD   
BM16.01 M 55 0/0 No 52 12.9 NMD   
BM17.01 F 15 3/3 No 34 >18.5* GP9 c.115 A>G p. Arg39Gly 
BM18.01 M 47 5/3 Yes 47 >18.5* GP9 c.83C>G  p.Ala28Gly 
BM19.01 F 27 0/0 No 55 >18.5* GP9 c.466G>C p. Ala156Pro 
BM20.01 M 25 4/2 No 140 12 NMD   
BM21.01 M 30 4/2 No 122 13.2 NMD   
BM22.01 F 45 0/0 No 106 12 NMD   
BM23.01 F 40 0/0 No 73 14 NMD   
BM24.01 F 23 0/0 No 103 13.9 NMD   
BM25.01 F 25 3/3 No 51 13 NMD   
BM26.01 M 35 0/0 No 52 15.5 GP1BA c. 28 G>C p.Leu10 Val 
BM27.01 F 18 3/4 yes 30 14.5 NMD   
BM28.01 F 52 0/0 No 36 16.5 NMD   
BM29.01 M 40 0/0 No 45 16 NMD   
BM30.01 F 9 4/2 No 83 16 ABCG5 c.293 C>G p.Ala98Gly
k
 
BM31.01 M 40 0/0 No 92 14 NMD   
BM32.01 M 35 4,5/3 Yes 107 13 NMD   
BM33.01 M 21 6/3 No 133 13 NMD   
BM34.01 M 22 0/0 No 95 13.9 NMD   
BM35.01 M 29 6/3 Tx No 42 >18.5* NMD   
BM36.01 F 24 3/2 No 97 13.6 NMD   
BM37.01 M 18 0/0 No 71 14 NMD   
BM38.01 F 45 0/0 No 51 15.6 ABCG5 c.293 C>G p.Ala98Gly
k
 
BM39.01 F 42 2/1 No 77 14 GP1BB c.320 G>C p.Arg107Pro 
BM40.01 F 19 6/3 Yes 65 13.9 GP9 c.527 T>G  p.Leu176Arg 
BM41.01 M 52 2/1 No 54 14.7 GP9 c.203 C>G p.Pro68Arg 
BM42.01 M 25 0/0 No 113 13.4 NMD   
BM43.01 M 30 0/0 No 128 12.9 NMD   
BM44.01 M 29 0/0 No 113 13.9 NMD   
BM45.01 F 25 2/1 No 125 13.3 NMD   
BM46.01 M 38 0/0 No 40 14.9 MYH9 c.5797 C>T p. Arg1933*
k
 
BM47.01 F 9 2,5/3 No 45 14 NMD   
BM48.01 M 30 0/0 No 67 13 NMD    
BM49.01 M 52 0/0 Yes 72 12 GP9 c.115A>G p. Arg39Gly 
BM50.01 M 38 6/3 No 71 14.2 ABCG5 c.1653 C>G p.Asn551Lys 
BM51.01 F 45 0/0 No 137 13.2 NMD   
BM52.01 F 48 0/0 No 103 13.9 NMD   
BM53.01 F 25 4/2 No 118 14.5 NMD   
BM54.01 M 57 6/3 No 65 >18.5* GP9 c.115A>G p. Arg39Gly 
BM55.01 M 50 4/2 Yes 115 14.3 NMD   
BM56.01 F 26 1,3/3 Yes 38 14.2 NMD   
BM57.01 F 34 4/2 No 147 13 GP9 c.290 G>C p.Arg97Pro 
BM58.01 M 59 0/0 No 131 14.2 NMD   
BM59.01 M 55 0/0 No 72 12.5 GP9 c.290 G>C p.Arg97Pro 
BM60.01 M 25 0/0 No 101 13 NMD   
BM61.01 M 23 0/0 No 110 14.2 GP9 c.185G>C p.Ser62Thr 
BM62.01 M 21 0/0 No 140 12 NMD   
BM63.01 M 24 0/0 No 105 15.3 GP9 c.185G>C p.Ser62Thr 
BM64.01 M 27 0/0 No 121 12 NMD   
BM65.01 F 28 0/0 No 78 13.8 NMD   
BM66.01 F 25 0/0 No 82 13.5 NMD   
BM67.01 F 25 5/3 Yes 67 13.9 GP1BA c.1360 C>T p.Pro454Ser 
BM68.01 M 40 4/2 No 83 >18.5* ABCG5 c.148C>T p.Arg50Cys
k
 
BM69.01 M 44 4/2 No 91 >18.5* GP1BB c.338A>T p.Tyr113Phe 
BM70.01 F 18 0/0 No 107 13.8 NMD   
BM71.01 M 21 0/0 No 88 12.8 GP9 c.290 G>C p. Arg97Pro 
BM72.01 F 34 1,3/3 Yes 80 13.9 NMD   
BM73.01 M 32 0/0 No 36 >18.5* NMD   
BM74.01 M 30 0/0 No 63 12.4 GP9 c.185G>C p.Ser62Thr 
BM75.01 M 19 5/3 No 53 >18.5* NMD   
BM76.01 F 8 0/0 No 49 >18.5* NMD   
BM77.01 M 30 0/0 No 131 14 GP9 c.228G>C p.Gln76His 
BM78.01 F 15 3,5,6/4 Tx No 47 >18.5* GP1BA c.638T>G p. Leu213Arg 
BM79.01 M 33 0/0 No 51 >18.5* NMD   
BM80.01 F 30 3,4/4 No 101 14.8 NMD   
BM81.01 M 17 2,4/2 No 140 13 NMD   
BM82.01 F 16 0/0 No 70 16.1 GP1BA c.1463T>G p.Leu488* 
BM83.01 M 42 0/0 No 80 12.8 ABCG5 c.148C>T p.Arg50Cys
k
 
BM84.01 M 40 0/0 No 125 13.6 NMD   
BM85.01 F 70 0/0 No 109 13 NMD   
BM86.01 M 45 0/0 No 132 12 NMD   
BM87.01 F 30 3/3 No 90 13 NMD   
BM88.01 F 32 4/2 No 105 12.1 NMD   
BM89.01 F 11 2/1 No 120 12.6 ABCG5 c.148C>T p.Arg50Cys
k
 
BM90.01 F 15 0/0 No 139 13.8 ABCG5 c.148C>T p.Arg50Cys
k
 
BM91.01 F 23 0/0 No 89 14 NMD   
BM92.01 F 16 0/0 No 90 13.1 NMD   
BM93.01 F 23 0/0 No 123 12 NMD   
BM94.01 F 19 0/0 No 78 >18.5* NMD   
BM95.01 M 12 0/0 No 98 >18.5* NMD   
BM96.01 F 20 0/0 No 110 14 ABCG5 c.148C>T p.Arg50Cys
k
 
BM97.01 F 14 0/0 No 136 12.9 NMD   
BM98.01 M 47 0/0 No 148 12.3 NMD   
BM99.01 M 58 0/0 No 134 12 NMD   
BM100.01 M 45 0/0 No 90 13 NMD   
BM101.01 F 48 0/0 No 83 13.5 MYH9 c.5836G>A p.Glu1946Lys 
BM102.01 F 36 2/1 No 67 13.1 MYH9 c.5797C>T p.Arg1933*
k
 
BM103.01 F 50 0/0 No 89 12.8 MYH9 c.5842G>A p.Asp1948Asn 
BM104.01 F 49 0/0 No 112 12.9 MYH9 c.5842G>A p.Asp1948Asn 
BM105.01 F 17 3/2 Tx No 150 12.5 MYH9 c.5842G>A p.Asp1948Asn 
BM106.01 M 15 0/0 No 198 >18.5* MYH9 c.5836G>A p.Glu1946Lys 
BM107.01 F 09 0/0 No 101 12.9 MYH9 c.5842G>A p.Asp1948Asn 
BM108.01 M 25 0/0 No 80 13.5 MYH9 c.5842G>A p.Asp1948Asn 
BM109.01 F 25 0/0 No 115 13.1 ABCG5 c.211G>A p.Asp71Asn 
BM110.01 F 35 4/2 No 76 14.1 ABCG5 c.211G>A p.Asp71Asn 
BM111.01 F 25 4/2 No 75 14 MYH9 c.5842G>A p.Asp1948Asn 
BM112.01 M 20 4/2 No 75 13.5 MYH9 c.5842G>A p.Asp1948Asn 
AOD: age of diagnosis; *: instrument did not measure MPV above 18.5fl; k : known mutation ; a: nucleotide A of the ATG translation initiation start site of the 
GP1BA (NM_000173.5), GP1BB (NM_000407.4), GP9 (NM_000174.3), ABCG5 (NM_022436.2) and MYH9 (NM_002473.4)  is indicated as nucleotide +1, 
(mutations are mapped to the immature protein structure of the gene); Tx: transfused; NR: normal range; NMD: no mutation detected. Clinical 
manifestations: 0. Asymptomatic 1. Easy Bruisability 2. Echymoses 3. Menorrhagia 4. Epistaxis 5. Prolonged bleeding after trauma 6. Frequent gum bleed. 
WHO (World Health Organisation): grade 0: no bleeding; grade 1: petechiae; grade 2: mild blood loss; grade 3: gross blood loss; grade 4: debilitating blood 
loss. 
 
 Table 3: Demographic and laboratory findings of included cases  
Parameters Median (IQR) 
Age (yrs) (n=112) 30 (8-70)    
Age Females (yrs)(n=55) 25(8-70)        
Age Males (yrs) (n=57) 30 (8-70)       
Platelet Count (X10
9
/L) (n=112) 89 (27-198)  
MPV (fl) (n=96) 13.25 (12-16.5)  
WHO Bleeding Score 0 (0-4)  
Screening Coagulation Assays (secs) (n=112)  
Prothrombin Time (PT) (NR: 12-14) 12.5 (11-13.9) 
Activated Partial Thromboplastin Time (APTT) (NR:28-33) 28.6 (25-32) 
Thrombin Time (TT)(NR: 15-19 ) 15.1 (12.9-18) 
Receptor Study (%) (n=112)  
GP1b  (CD42b) (NR: 50-150) 75.3 (42.9-98.6) 
GPIIb/IIIa (CD41a) (NR: 50-150) 80.5(34.6-98.8) 
GPIX (CD42a) (NR: 50-150) 79.35 (27.3-98.0) 
Genes  Platelet Count (X10
9
/L) 
GP1BA (n=4) 59.50 (47-70) 
GP1BB (n=3) 77.0 (77-91) 
GP9 (n=18) 65.50 (34-147) 
ABCG5 (n=12) 83.0 (51-140) 
MYH9 (n=11) 83.0 (40-198) 
  
IQR denotes the 25
th
 and 75
th
 interquartile range and n denotes no. of patients; NR: Normal Range 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Statistical Analysis of known Single Nucleotide Variants in cases with congenital 
macrothrombocytopenia and normal controls from India 
Polymorphic Marker Alleles Odds ratio for risk allele 
(95% confidence Interval) 
P 
Value 
Gene Mutation/Polymorphism Risk/Non 
risk 
  
GP1BA rs6065  T/C 1.300 (0.3126 to 5.406) 1.00 
 rs2243093  C/T 0.4318 (0.1350 to 1.381) 1.00 
GP9 rs3796130 A/G 0.1270 (0.03156 to 0.5109) 0.0034* 
 rs6069  A/G 0.1598 (0.06936 to 0.3681) < 0.0001* 
ABCG5 rs6720173  C/G 1.263 (0.6450 to 2.473) 0.6095 
 rs56200894  C/G 1.000 (0.06164 to 16.224) 1.0000 
TUBB1 p.Gln43Pro  P/Q 1.111 (0.7432 to 1.659) 0.682 
*Statistically Significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5: Prediction of the nature of novel missense mutations in Congenital 
Macrothrombocytopenia cases from India  
 Heterozygous Variations in  Congenital Macrothrombocytopenia Cases 
Gene Protein POLYPHEN2 
(Score: 0-1) 
SIFT ALIGN GVGD 
 
MUPRO/I-Mutant 2.0 
(Stability of Protein Structure) 
 
GP1BA p. Leu10Val Dam (0.99) Int Del Decreases stability 
 p.Pro454Ser Dam(0.99) Int Del Decreases stability 
 p.Leu213Arg Dam  (1) Int Del Decreases stability 
GP1BB p.Cys95Trp Dam (0.99) Int Del Decreases Stability 
 p.Arg107Pro Dam (0.99) Int Del Decreases stability 
 p.Tyr113Phe Dam (0.99) Int Del Decreases stability 
GP9 p.Ser62Thr Dam (0.99) Int Del Decreases stability 
 p.Leu49Arg Dam (0.99) Int Del Decreases stability 
 p.Arg97Pro Dam(0.99) Int Del Decreases stability 
 p.Arg39Gly Dam (0.67) Int Del Decreases stability 
 p.Ala28Gly Dam (0.89) Int Del Decreases the stability 
 p.Ala156pro Dam(0.95) Int Del Deceases the stability 
 p.Leu176Arg Benign(0.00) Bord Uncla Decreases the stability 
 p.Pro68Arg Dam(0.99) Int Del Decreases the stability 
 p.Gln76His Benign(0.208) Bord Uncla Decreases the stability 
 p.Ala156Thr Dam (0.688) Bord Uncla Decreases the stability 
ABCG5 p.Asn551Lys Dam(0.92) Int Del Decreases the stability 
 p.Arg50Cys Dam(0.99) Int Del Decreases the stability 
 p.Ala98Gly Dam (0.99) Int Del Decreases the stability 
 p.Asp71Asn Dam (0.99) Int Del Decreases the stability 
MYH9 p.Glu1946Lys Benign(0.208) Bord Uncla Decreases the stability 
 p.Asp1948Asn Dam (0.98) Int Del Decreases the stability 
Dam: Damaging; Int: Intolerant; Uncla: Unclassified; Del: Deleterious; Bord: Borderline 
 
 
 
 
 
 
 
 
 
  
 
Figure 1: Distribution of Congenital Macrothrombocytopenia cases across India, most 
concentrated towards Eastern India (West Bengal, Assam, Bihar, Jharkhand, and Orissa) 
 
 
  
Figure 2: A family tree showing dominant mode of inheritance in a Bengal Macrothrombocytopenia 
(BM15.01) family 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3: Blood films of case A. showing giant platelets and Case B. showing giant platelets 
and stomatocytes in their RBCs 
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(B) 
Figure 4: WHO Bleeding Score in relation to the degree of (A). Mean Platelet Volume (MPV) 
and (B). Thrombocytopenia in congenital macrothrombocytopenia cases from India 
 
 
